Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972


Spotlight on Scrip Perspectives 24/25





Focus On Asia


Roche Accelerator Deepens Pool Of Potential Chinese Partners

Roche's Shanghai-based Accelerator now includes close to 20 Chinese startups across multiple areas including novel modalities and AI-based research, fitting into the Swiss major's strategy of partnering in core areas to access innovation.

Data Analysis


R&D


Will BioVersys Listing Wake Europe From Its IPO Slumber?

 
• By 

The Swiss firm’s plans to go public are a boost for the antibiotics space and for hopes that the continent’s biotechs may follow their US counterparts and find financial solutions on the capital markets.

J&J Expands Ketamine Case With Spravato Monotherapy Indication

 
• By 

On the US market since 2019 for treatment-resistant depression in tandem with oral antidepressants, J&J’s new indication allows for more flexibility.

Pipeline Watch: Six Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Roche Accelerator Deepens Pool Of Potential Chinese Partners

 
• By 

Roche's Shanghai-based Accelerator now includes close to 20 Chinese startups across multiple areas including novel modalities and AI-based research, fitting into the Swiss major's strategy of partnering in core areas to access innovation.

Business


J&J Expects Revenue Growth Despite Stelara Biosimilars, IRA Impact

 
• By 

Innovative medicine grew 4% during Q4 2024 and brought in $57bn during the full year, one year ahead of internal projections. Spravato topped the blockbuster mark in its fifth year on market.

Servier Plots Route Into Neurology Through BD

 

CEO David Lee, who oversees Servier’s US business, and chief scientific officer Claude Bertrand talked to Scrip at J.P. Morgan about expanding into neurology through business development.

Tris Looks To Take On Opioids With Latest Cebranopadol Data

 

The company’s CEO and chief business officer said the company is already in talks with multiple potential partners for ex-US markets.

Will BioVersys Listing Wake Europe From Its IPO Slumber?

 
• By 

The Swiss firm’s plans to go public are a boost for the antibiotics space and for hopes that the continent’s biotechs may follow their US counterparts and find financial solutions on the capital markets.

Scrip Originals


Pipeline Watch: Six Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Stock Watch: J&J, GSK, Lilly Bring J.P. Morgan Cheer

 
• By 

After a less auspicious prelude and a positive start to the biggest healthcare conference of the year, the news flow and investors’ support for biotech initially improved.

Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku

 

Plus deals involving Simcere/AbbVie, Daiichi Sankyo/Glycotope, Telix/ImaginAb, Harbour/Kelun/Windward, Insilico/Menarini, Samsung Bioepis/Teva, HealZen/J&J, Zai Lab/Vertex, Zai Lab/MediLink and Primrose/Serum Institute of India.

Executives On The Move: Five CMOs, 14 CEOs And 23 CFOs Among This Week’s Changes

Latest updates include changes at the top at Neuphoria Therapeutics, plus new CEOs at Cyclacel Pharmaceuticals and Norgine, among others.